Jazz Pharmaceuticals (NASDAQ:JAZZ) PT Raised to $190.00 at JPMorgan Chase & Co. : vimarsana.com

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) had its price objective lifted by equities research analysts at JPMorgan Chase & Co. from $170.00 to $190.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has an “overweight” rating on the specialty pharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price […]

Related Keywords

United States , Stifel Nicolaus , Patricia Carr , Philipl Johnson , Covestor Ltd , Securities Exchange Commission , News Ratings For Jazz Pharmaceuticals Daily , Jpmorgan Chase Co , Jazz Pharmaceuticals , Jazz Pharmaceuticals Trading , Analyst Recommendations For Jazz Pharmaceuticals , Cantor Fitzgerald , Cape Investment Advisory Inc , St Germaindj Co , Jazz Pharmaceuticals Company Profile , Needham Company , Get Free Report , Exchange Commission , Investment Advisory , Wealth Management , Jazz Pharmaceuticals Daily , Nasdaq Jazz , Jazz , Medical , G5087110 , Boost Price Target , Jpmorgan Chase Co ,